2024-02-12 01:34:26 ET
Summary
- Cellectar Biosciences is a developmental biotech focused on a radiolabeled phospholipid for hematologic malignancies, with a focus on Waldenstrom's macroglobulinemia.
- Their most advanced development is in Waldenstrom's, with positive trial results and plans to file for Accelerated Approval.
- The company has a strong chance at approval but faces cash concerns and the challenge of a small market size for its drug.
Topline Summary
Read the full article on Seeking Alpha
For further details see:
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss